Anaconda Biomed Secures $56 Million Financing from New and Existing Investors

Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio
 
BARCELONA, Spain and MARIN, Calif. – September 23, 2026 – Anaconda Biomed, a medical technology company developing a next-generation portfolio of novel thrombectomy catheters based on its core funnel catheter technology platform, today announced the closing of a $56 million financing round with participation from new and existing investors. Proceeds will support product development and clinical work, including completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.
© Optimum Strategic Communications.